Document Page: First | Prev | Next | All | Image | This Release | Search
File: 123096_sep96_decls23_0009.txt
Subject: DIAGNOSIS AND TREATMENT OF DISEASES OF IMPORTANCE
Unit: OTSG
Parent Organization: HSC
Box ID: BX003203
Folder Title: DIAGNOSIS AND TREATMENT OF DISEASES 1991PORTABLE FIELD PERSONNEL SHOWER SYSTEMS
Document Number: 1
Folder Seq #: 88
VII. Disposition: A. No complications: limited duty Congo Crimean Hemorrhagic FOVer (CCJIF)
(consider EVAC). 1. Communicability;
B. Complications: hospitalization and
EVAC. A. Route:
vil. Prognosis: A. Treated: excellent. 1. Ixodid tick f@o me species) bite:
B. Untreated: 30% complications, prolonged 2. Exposure to blood, secretions, or excrement of
hospitalization and convalescence with infected Patients. Aerosol transmission may
occasional deaths due to endocarditis. occur, as transmission to hospital staff has been
documented in the absence of direct patient
IX. Public health measures: contact.
Locate contaminated products, if implicated, and destroy; 3. Exposure to tissue r blood of infected animals.
educate troops not to drink or eat unpasteurized dairy B. Isolation:
products; report to Preventive Medicine. Not communicable 1. Strict isolation mandatory, to include contact,
from person to person. blood, body fluids, and respiratory. This must
include strict precautions in handling of clinical
laboratory specimens.
C. Prophylaxis:
1. No prophylaxis of proven efficacy is available.
2. Hyperimmune convalescent erum:
a. Isolated clinical reports suggest that
administration of hyperimmune convalescent
human serum may be protective. Definitive
indications and dosage regimen have not been
established.
b. 250 ml administered IV over 1 to 2 hours,
possibly repeated once in 12 hours ay
beneficial.
roblems include:
i. Inability to ascertain antiviral titers
in transfused serum.
ii. Hypersensitivity reactions.
iii. Transmission of other blood-b,r,,
illnesses,
3. Ribavirin:
a. Ribavirin, an antiviral drug, may be effec-
tive. Definitive clinical studies have not
yet been accomplished but preliminary studies
show promise.
b. Post exposure Prophylaxis should be strongly
cons idered for health care workers and
transporting Personnel involved in caring for
patients with CCHF. Prophylaxis should be
begun as soon as possible after exposure.
C. Suggested Post-exposure prophylaxis dosage
regimen: 400 mg PO Q6h for 24 hours, then
400 mg PO TID for 6 day,.
d. Adverse effects include: teratogenicity,
possible embryotoxicity, reversible meet,-
cytic anemia, extravascular hemolysis,
9
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 52 f:/Week-36/BX003203/DIAGNOSIS AND TREATMENT OF DISEASES 1991PORTABLE FIELD PERSONNEL SHOWER SYSTEMS/diagnosis and treatment of diseases of importanc:12179609281524
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = DIAGNOSIS AND TREATMENT OF DISEASES 1991PORTABLE FIELD PERSONNEL SHOWER SYSTEMS
Folder Seq # = 88
Subject = DIAGNOSIS AND TREATMENT OF DISEASES OF IMPORTANC
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 17-DEC-1996